Arieh S Solomon, Ari Barzilai, Itai Benhar, Hagit Sacks, Yohann Aouat, Angel Messeuger, Michael Burnet and Mirea Coma
Tel Aviv University, Israel
Nicast Ltd, Israel
CSIC ΓΆΒ?Β? QAC, Spain
Synovo GmbH Tubingen, Germany
Anaxomics SL, Spain
Scientific Tracks Abstracts: Neurochem Neuropharm
Background: Semaphorin-3A is a leading factor in the apoptotic death program of the neural cells in CNS. It is right to suppose that inhibition of Sema3A expression in the right time window will reduce the death of a great population of neural cells following assault. Purpose: The aim is to develop low molecular weight inhibitor of Sema3A and produce function blocking Sema3A human antibodies and manufacture a biodegradable polymeric implant for controlled release of Sema3A inhibitor. Material & Methods: We used laboratory rats and rabbits and created acute and chronic assault to the optic nerve. Following the assault we injected the substances mentioned above in the injured eye. Results: We present the methods of creating the low MW inhibitors of Sema3A and the Sema3A antibodies. The creation of the implants is shown. We present here the positive inhibitory activity of these substances in vitro and in vivo experiments.
Arieh S Solomon initiated research in studying the degeneration and regeneration process of the optic nerve , following assaults. He concepted a new type of intra ocular implant to treat glaucoma (the blinding disease creating high IOP and killing the optic nerve ). He concepresd a new type and method of ecalauting glaucoma damage in people. All were awarded patents in US, Europe, and other countries. Dr. Solomon has 100 publications in various international journals.
Email: ariehso@netvision.net.il
